Gujarat Themis Biosyn Board Approves FY26 Audited Results, Recommends 67% Dividend
Gujarat Themis Biosyn approved audited financial results for FY26. The Board recommended a final dividend of ₹0.67 per share, totaling ₹7.30 crore. The company also approved the appointment of a new cost auditor and a preferential issue of equity shares to non-promoters.
The recommended dividend and the proposal for a preferential issue are significant corporate actions that could impact the company's financial structure and shareholder value. The approval of audited results is a routine but important update.
The company announced positive financial results and recommended a dividend, indicating financial health and a commitment to shareholder returns. The approval of a preferential issue also signals potential for future growth and funding.
Gujarat Themis Biosyn Limited announced the outcome of its Board Meeting held on May 25, 2026, where the Audited Financial Results for the quarter and year ended March 31, 2026, were approved. The Board recommended a final dividend of ₹0.67 per equity share (67%) for the financial year ended March 31, 2026, amounting to ₹7,30,06,728. This dividend is subject to shareholder approval at the upcoming Annual General Meeting.
Additionally, the Board approved the appointment of M/s. Raja Dutta & Co. as the Cost Auditor for the Financial Year 2026-27. A significant decision was the approval of a proposal for a preferential issue of equity shares to Non-Promoters, with a committee being constituted to finalize the terms and conditions. The meeting commenced at 11:30 AM and concluded at 3:00 PM.
What to do with a filing like this
Gujarat Themis Biosyn Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gujarat Themis Biosyn Limited. Read the original for the full detail.